These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29409686)

  • 1. LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse model.
    Tsukahara R; Yamamoto S; Yoshikawa K; Gotoh M; Tsukahara T; Neyama H; Ishii S; Akahoshi N; Yanagida K; Sumida H; Araki M; Araki K; Yamamura KI; Murakami-Murofushi K; Ueda H
    J Pharmacol Sci; 2018 Feb; 136(2):93-96. PubMed ID: 29409686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents.
    Murai N; Hiyama H; Kiso T; Sekizawa T; Watabiki T; Oka H; Aoki T
    Neuropharmacology; 2017 Nov; 126():97-107. PubMed ID: 28859883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of LPA1 receptor signaling in cerebral ischemia-induced neuropathic pain.
    Halder SK; Yano R; Chun J; Ueda H
    Neuroscience; 2013 Apr; 235():10-5. PubMed ID: 23318243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain.
    Lin ME; Rivera RR; Chun J
    J Biol Chem; 2012 May; 287(21):17608-17617. PubMed ID: 22461625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidic acid-induced itch is mediated by signalling of LPA
    Kittaka H; Uchida K; Fukuta N; Tominaga M
    J Physiol; 2017 Apr; 595(8):2681-2698. PubMed ID: 28176353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice.
    Uchida H; Nagai J; Ueda H
    Mol Pain; 2014 Nov; 10():71. PubMed ID: 25411045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain.
    Velasco M; O'Sullivan C; Sheridan GK
    Neuropharmacology; 2017 Feb; 113(Pt B):608-617. PubMed ID: 27059127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysophosphatidic acid as the initiator of neuropathic pain.
    Ueda H
    Biol Pharm Bull; 2011; 34(8):1154-8. PubMed ID: 21804198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophosphatidic Acid Receptor 1- and 3-Mediated Hyperalgesia and Hypoalgesia in Diabetic Neuropathic Pain Models in Mice.
    Ueda H; Neyama H; Matsushita Y
    Cells; 2020 Aug; 9(8):. PubMed ID: 32824296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of spinal substance P pain transmission under the condition of LPA1 receptor-mediated neuropathic pain.
    Inoue M; Yamaguchi A; Kawakami M; Chun J; Ueda H
    Mol Pain; 2006 Aug; 2():25. PubMed ID: 16914035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin F2α FP receptor inhibitor reduces demyelination and motor dysfunction in a cuprizone-induced multiple sclerosis mouse model.
    Iwasa K; Yamamoto S; Takahashi M; Suzuki S; Yagishita S; Awaji T; Maruyama K; Yoshikawa K
    Prostaglandins Leukot Essent Fatty Acids; 2014 Nov; 91(5):175-82. PubMed ID: 25224839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of chemoresistance by lysophosphatidic acid (LPA) signaling through LPA
    Minami K; Ueda N; Maeda H; Ishimoto K; Otagaki S; Tsujiuchi T
    Biochem Biophys Res Commun; 2019 Sep; 517(2):359-363. PubMed ID: 31362892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional regulation of glutamate signaling during cuprizone-induced demyelination in the brain.
    Azami Tameh A; Clarner T; Beyer C; Atlasi MA; Hassanzadeh G; Naderian H
    Ann Anat; 2013 Oct; 195(5):415-23. PubMed ID: 23711509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal monitoring of metabolic alterations in cuprizone mouse model of multiple sclerosis using 1H-magnetic resonance spectroscopy.
    Orije J; Kara F; Guglielmetti C; Praet J; Van der Linden A; Ponsaerts P; Verhoye M
    Neuroimage; 2015 Jul; 114():128-35. PubMed ID: 25871629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine.
    Nagai J; Uchida H; Matsushita Y; Yano R; Ueda M; Niwa M; Aoki J; Chun J; Ueda H
    Mol Pain; 2010 Nov; 6():78. PubMed ID: 21062487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.
    Yang XY; Zhao EY; Zhuang WX; Sun FX; Han HL; Han HR; Lin ZJ; Pan ZF; Qu MH; Zeng XW; Ding Y
    Neurol Sci; 2015 Nov; 36(11):2027-33. PubMed ID: 26169757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LPA5 receptor plays a role in pain sensitivity, emotional exploration and reversal learning.
    Callaerts-Vegh Z; Leo S; Vermaercke B; Meert T; D'Hooge R
    Genes Brain Behav; 2012 Nov; 11(8):1009-19. PubMed ID: 23039190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of lysophosphatidic acid receptor 5 is necessary for the regulation of intestinal Na
    Jenkin KA; He P; Yun CC
    Am J Physiol Gastrointest Liver Physiol; 2018 Oct; 315(4):G433-G442. PubMed ID: 29792531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17β-Estradiol enhances the efficacy of adipose-derived mesenchymal stem cells on remyelination in mouse model of multiple sclerosis.
    Ragerdi Kashani I; Hedayatpour A; Pasbakhsh P; Kafami L; Atlasi N; Pirhajati Mahabadi V; Mamoudi R; Baazm M
    Acta Med Iran; 2012; 50(12):789-97. PubMed ID: 23456519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LPA
    Minami K; Ueda N; Ishimoto K; Tsujiuchi T
    Exp Cell Res; 2020 Mar; 388(1):111813. PubMed ID: 31904382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.